People · Operator
Named in public records as an officer, director or promoter · active 2019–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sycamore Biopharma, Inc. | — | Biotechnology | Pre-Seed | $675K | $6.4M | 2019 |
Mark T. Hamann at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark T. Hamann on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Chris Sadek | 1 | 1 |
| William T. Lamar | 1 | 1 |
| R. Tyler Stone III | 1 | 1 |
| H. Lee T. Mashburn, Jr. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.